Silo pharma achieves new milestone for sp-26 therapeutic -initiates ind enabling study of topical ketamine formulation

Englewood cliffs, nj, nov. 11, 2022 (globe newswire) -- silo pharma, inc. (nasdaq: silo) (“the company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced initial dosing in its ind-enabling study of sp-26, its novel time-released, topical formulation of ketamine.
SILO Ratings Summary
SILO Quant Ranking